Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
Zealand Pharma A/S has announced the total number of shares and voting rights as of February 28, 2021, in compliance with Danish Capital Markets Act. The company reported a total of 43,400,547 shares and voting rights, which corresponds to a nominal share capital of DKK 43,400,547. This announcement follows a previous update regarding an increase in share capital due to employee warrant exercises. Zealand Pharma specializes in innovative peptide-based medicines and has a strong pipeline, with several candidates in clinical development.
Zealand Pharma hosted a virtual R&D Day on March 5, 2021, featuring a live Q&A session available for analysts and investors.
Prerecorded materials detailing Zealand's development pipeline and five-year R&D strategy are accessible on its website. The virtual event includes insights from various executives about the company's ambitious plans for 2025 and its peptide-based medicines for metabolic and gastrointestinal diseases. Zealand Pharma aims to enhance its market position backed by collaborations with major pharmaceutical companies.
Zealand Pharma announced a conference call on March 11, 2021, at 4 PM CET (10 AM ET) to present its Full Year Results for 2020. Senior executives, including President Emmanuel Dulac and CFO Matt Dallas, will discuss the results followed by a Q&A session. Participants can join via multiple dial-in numbers provided for various countries, and a live audio webcast will be available on Zealand's Investor website. A recording and transcript will follow.
Zealand Pharma A/S (Nasdaq: ZEAL) announced its participation in two upcoming investor conferences in March 2021. The Credit Suisse 2021 London Global Healthcare Conference will take place on March 2, while the Jefferies Pan-European Mid-Cap Virtual Conference is scheduled for March 30. Zealand Pharma is focused on innovative peptide-based medicines and has advanced multiple drug candidates into clinical development, including V-Go, an insulin delivery option for diabetes patients.
Zealand Pharma A/S (Nasdaq: ZEAL) announced its participation in the SVB Leerink 9th Annual Global Healthcare Conference on February 24, 2021. Members of Zealand's senior management will present virtually at 8:00 a.m. ET. A live webcast can be accessed on the company’s website, with a replay available after the event. Zealand focuses on developing peptide-based medicines and is advancing multiple drug candidates, including one under review for regulatory approval in the U.S.
Zealand Pharma A/S (Nasdaq: ZEAL) announced the disclosure of transactions conducted by managerial personnel and their associates concerning the company's shares. This announcement is part of compliance with regulatory requirements and does not indicate any significant changes in management strategy or financial performance. Zealand Pharma, focused on innovative peptide-based medications, boasts a robust pipeline with over ten candidates in clinical development, two of which are already on the market. For further details, consult the attached documents.
Zealand Pharma will host a virtual R&D Day on March 5, 2021, showcasing progress in its R&D pipeline and its five-year strategy. The event will include a pre-recorded session, accessible on March 4, followed by a live Q&A session at 4:00 p.m. CET (10:00 a.m. ET). This aims to provide analysts and investors with insights into Zealand's innovative peptide-based medicines, including candidates in late-stage development and ongoing regulatory reviews in the U.S.
For more information, visit the Events & Presentations page on Zealand's website.
Zealand Pharma has completed a capital increase of DKK 3,600,841 through the issuance of 3,600,841 new ordinary shares. Following this increase, the company's total share capital now stands at DKK 43,400,547, totaling 43,400,547 shares. The new shares will be admitted to trading on Nasdaq Copenhagen with their permanent ISIN code, expected to merge with the temporary code by February 3, 2021. The offering was managed by Goldman Sachs International, Jefferies GmbH, and Danske Bank A/S.
Zealand Pharma A/S (NASDAQ: ZEAL) announced changes to its share capital, effective September 30, 2020. The total number of shares has increased to 39,778,961, with corresponding voting rights also at 39,778,961. This increase is attributed to the exercise of employee warrants as previously disclosed in Company announcement No. 48/2020. Zealand focuses on innovative peptide-based medicines and has multiple candidates in late-stage development.
Summary not available.